Slide 1: Q4 2023 results presentation
January 2023 – December 2023 – Q4 2023 results presentation
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "beli
Slide 3: Agenda
Agenda Q4 in short Business updates Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q4 in short
Q4 in short Q1 Q2 Q3 Q4 4
Slide 5: Quarterly progress
The Group is proud to have achieved another milestone by becoming both significantly cash-flow positive and profitable in the quarter, reflecting our astute financial discipline leading to sustainable success 22% 325K 26% Adjusted EBITDA YTD Full Year organic Q4 2023 cash flow increased to €3.9m rev
Slide 6: Business updates
Business updates 4b Physitrack
Slide 7: Our two business lines positioned for digital healthcare demand
Our two business lines have us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges Q@= Mental Wellbeing ‘Your Results mel sn wo ae then nd ae =I ! = ero = Lifecare Wellness Seamless and One platform, All ’ Efficient care areas of employee " Soluti
Slide 8: Lifecare quarterly developments
Lifecare quarterly developments Q4 Highlights: 14% growth in license numbers within • During the quarter there has been rapid development of our AI co-pilot tool, paving the way for new user growth in market segments that need a helping hand with Lifecare recommended exercise programs via a powerful
Slide 9: Wellness quarterly developments
Wellness quarterly developments Q4 Highlights: YTD revenue, Wellness segment 6.0 • The quarter marked 18 months since the last Wellness acquisition (Champion Health), with 41% quarter-on-quarter revenue growth being solely organic. We are pleased with the 5.0 continuous margin expansion of the divis
Slide 10: Recruitment drive
Recruitment drive • As the business grows and scale-ups the business needs a strong team around it to support its growth efforts • As we look for efficiencies within the business we have brought a number of tasks in house, and with this have had a recent recruitment drive. • We have received hundred
Slide 11: Financial Results
Financial Results Q1 Q2 Q3 Q4 1 1
Slide 12: Q4 Financial Highlights
Q 1 2 Q4 Financial Highlights 3 month revenue 3 Month EBITDA 11% 270% €3.8m (Q4 2022: €3.5m) Organic €4.8m (Q4 2022: €1.3m) YTD Operating cashflow YTD organic revenue growth 22% 82% €2.6m (Q4 2022: €1.5m) 3 month adjusted EBITDA 3 month adjusted EBITDA margin 12% +1pp €1.0m (Q4 2022: €0.9m) 26% (Q4
Slide 13: Maintaining revenue growth
Q 1 2 Maintaining revenue growth In-line with medium term growth targets Group Revenue 4.5 Lifecare revenue growth 3.0 Wellness revenue growth 2.5 22% 4.0 13% 2.5 2.0 3.5 3.0 2.0 44% 1.5 2.5 1.5 2.0 1.0 1.5 1.0 1.0 0.5 0.5 0.5 - - - Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 14: EBITDA
Q 1 2 EBITDA Continued strong growth 8.0 7.0 6.0 (€3.2M) 178% 5.0 €1.3M €2.6M €'million €7.1M 4.0 82% 13% 3.0 €0.9m €3.4m €3.9M 2.0 ADJUSTED EBITDA €2.5m Margin ADJUSTED EBITDA 1.0 Margin 28% 26% - 12 MONTHS 2022 EBITDA Adjusting it ems* 12 MONTHS 2022 Adjusted 12 MONTHS 2023 EBITDA Adjusting it ems
Slide 15: Adjusted EBITDA
Q 1 2 Adjusted EBITDA 4.5 4.0 13% EBITDA by division 3.5 1.0 4.4 46% 3.0 0.9 Q4 2023 0.4 7% 2.5 1.1 (0.9) 2.0 0.9 1.5 49% 1.0 4.3 0.9 1.0 Q4 2022 0.1 2% (0.9) 0.5 0.9 0.7 - (2.0) (1.0) - 1.0 2.0 3.0 4.0 5.0 2022 ADJ EBITDA 2023 ADJ EBITDA Lifecare Wel lness Group Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 16: Cashflow
Q 1 2 Cashflow 5.0 (0.4) 4.0 (0.3) 3.0 3.9 Available liquidity 2.0 (3.4) €2.4m €1.9m undrawn on facility 1.9 1.0 - 0.6 2.6 0.5 - 1 Jan 2023 Opening Net Adjusted EBITDA Working capital Interest expense Purchase of intangibles Deferred consideration Adjusting it ems Net drawdown of Fx 31 December 2023
Slide 17: Exited the financial year with positive free cash-flow
Q 1 2 Exited the financial year with positive free cash-flow 0.4 0.2 - Q122 Q222 Q322 Q422 Q123 Q223 Q323 Q423 (0.2) (0.4) (0.6) (0.8) (1.0) (1.2) (1) Free cash flow is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipment and finance cos
Slide 18: Cash outlook
Q 1 2 Cash outlook 1.5 1.0 0.5 - 2022 2023 2024 (0.5) (1.0) (1.5) (2.0) (2.5) (3.0) (3.5) Expectation the Group will be cash-flow positive for the 2024 financial year, despite there being quarterly fluctuations. 18 Q1 Q2 Q3 Q3 Q4
Slide 19: Balance sheet
Q 1 2 Balance sheet 31 December 2023 31 December 2022 Euros '000 Goodwill, intangibles and PPE 34,251 37,738 Cash and cash equivalents 536 578 Borrowings (3,578) (832) Trade and other receivables 3,917 2,997 Trade and other payables (2,625) (2,212) Deferred revenue (2,201) (2,061) Deferred tax (1,18
Slide 20: Strategy and outlook
Strategy and outlook Q1 Q2 Q3 Q4 20
Slide 21: Our unique value proposition
Our unique value proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes, through more personalized, data-driven care Positioned to capitalize on grow
Slide 22: How it all comes together - investing in Physitrack
How it all comes together - investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Growing market supported Physitrack aims to achieve annual organic 1. Market growth dynamics by underlying macro sales growth exceeding 30% in the medium trends t
Slide 23: Q&A
Q&A Q1 Q2 Q3 Q4 23